Sarepta Therapeutics, Inc. (SRPT)
Every figure below is the company's own, as filed. Nothing is estimated and
nothing is smoothed — a period the filing does not support is left blank rather than
drawn.
Quarters are the company's own, counted from its financial
year ending 12-31.
Amounts in USD.
Every figure as a table ›
Revenue Quarterly
0
300M
600M
900M
Q3 '21: 189.4M
Q4 '21: 201.5M
Q1 '22: 210.8M
Q2 '22: 233.5M
Q3 '22: 230.3M
Q4 '22: 258.4M
Q1 '23: 253.5M
Q2 '23: 261.2M
Q3 '23: 331.8M
Q4 '23: 396.8M
Q1 '24: 413.5M
Q2 '24: 362.9M
Q3 '24: 467.2M
Q4 '24: 658.4M
Q1 '25: 744.9M
Q2 '25: 611.1M
Q3 '25: 399.4M
Q4 '25: 442.9M
Q1 '26: 730.8M
Q2 '26: 401.3M
Q4 '21
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
Gross Profit Quarterly
-200M
0
200M
400M
600M
Q1 '24: 308.9M
Q2 '24: 316M
Q3 '24: 338.1M
Q4 '24: 505.9M
Q1 '25: 474M
Q2 '25: 360.6M
Q3 '25: 219.3M
Q4 '25: -29.1M
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Operating Income Quarterly
-450M
-300M
-150M
0
150M
300M
450M
Q3 '21: -34.5M
Q4 '21: -105.8M
Q1 '22: -86.9M
Q2 '22: -211.1M
Q3 '22: -131.4M
Q4 '22: -106.8M
Q1 '23: -138.1M
Q2 '23: -133.5M
Q3 '23: -20.8M
Q4 '23: 24.6M
Q1 '24: 34.9M
Q2 '24: -701K
Q3 '24: 22.2M
Q4 '24: 161.7M
Q1 '25: -300.4M
Q2 '25: 115.6M
Q3 '25: -103.4M
Q4 '25: -411.6M
Q1 '26: 358.4M
Q2 '26: 13.3M
Q4 '21
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
Net Income Quarterly
-600M
-400M
-200M
0
200M
400M
600M
Q3 '21: -48.1M
Q4 '21: -122M
Q1 '22: -105M
Q2 '22: -231.5M
Q3 '22: -257.7M
Q4 '22: -109.2M
Q1 '23: -516.8M
Q2 '23: -23.9M
Q3 '23: -40.9M
Q4 '23: 45.7M
Q1 '24: 36.1M
Q2 '24: 6.5M
Q3 '24: 33.6M
Q4 '24: 159M
Q1 '25: -447.5M
Q2 '25: 196.9M
Q3 '25: -179.9M
Q4 '25: -412.2M
Q1 '26: 331M
Q2 '26: -4.9M
Q4 '21
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
Operating Cash Flow Quarterly
-600M
-400M
-200M
0
200M
400M
600M
Q3 '21: -124.3M
Q4 '21: -29.3M
Q1 '22: -101.2M
Q2 '22: -66.8M
Q3 '22: -65M
Q4 '22: -92.4M
Q1 '23: -209.4M
Q2 '23: -122.2M
Q3 '23: -114.7M
Q4 '23: -54.7M
Q1 '24: -242.1M
Q2 '24: 14.9M
Q3 '24: -70.7M
Q4 '24: 92M
Q1 '25: -583.4M
Q2 '25: 261.3M
Q3 '25: -14.6M
Q4 '25: 131.2M
Q1 '26: -202.7M
Q2 '26: 197.1M
Q4 '21
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
Free Cash Flow Quarterly
-750M
-500M
-250M
0
250M
500M
750M
Q3 '21: -133.6M
Q4 '21: -31.5M
Q1 '22: -106.7M
Q2 '22: -75.9M
Q3 '22: -73.2M
Q4 '22: -100.4M
Q1 '23: -218.9M
Q2 '23: -140.1M
Q3 '23: -144.4M
Q4 '23: -73.7M
Q1 '24: -274.5M
Q2 '24: -14.2M
Q3 '24: -108M
Q4 '24: 54M
Q1 '25: -627.1M
Q2 '25: 229.5M
Q3 '25: -37.5M
Q4 '25: 127.6M
Q1 '26: -204.8M
Q2 '26: 196.5M
Q4 '21
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
Operating cash flow minus capital expenditure.
Shares Outstanding Quarterly
0
50M
100M
150M
Q1 '20: 76.4M
Q2 '20: 78M
Q3 '20: 78.5K
Q1 '21: 79.5K
Q2 '21: 79.7K
Q3 '21: 79.9K
Q1 '22: 87.3M
Q2 '22: 87.5M
Q3 '22: 87.6M
Q1 '23: 88.2M
Q2 '23: 88.7M
Q3 '23: 88.9M
Q1 '24: 99.1M
Q2 '24: 99.1M
Q3 '24: 100.4M
Q1 '25: 97.4M
Q2 '25: 106.6M
Q3 '25: 100.2M
Q1 '26: 121.9M
Q2 '26: 105.4M
Q2 '20
Q2 '21
Q2 '22
Q2 '23
Q2 '24
Q2 '25
Q2 '26
Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.
EPS TTM
-15.00
-10.00
-5.00
0.00
5.00
10.00
15.00
Q3 '19: -8.56
Q4 '19: -9.67
Q1 '20: -8.83
Q2 '20: -7.02
Q3 '22: -8.22
Q4 '22: -8.03
Q1 '23: -12.69
Q2 '23: -10.31
Q3 '23: -7.83
Q4 '23: -5.80
Q1 '24: 0.43
Q2 '24: 0.77
Q3 '24: 1.57
Q4 '24: 2.28
Q1 '25: -2.69
Q2 '25: -0.87
Q3 '25: -3.01
Q4 '25: -8.44
Q1 '26: -0.96
Q2 '26: -2.90
Q4 '19
Q3 '22
Q2 '23
Q1 '24
Q4 '24
Q3 '25
Q2 '26
The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.
Not drawn for SRPT:
Cost of Revenue . Nothing in this filer's XBRL supports
it for the periods asked for. That is a gap in
the filing, not a zero, and drawing a flat line would be an invention.